Sector
PharmaceuticalsOpen
₹515Prev. Close
₹516Turnover(Lac.)
₹151.93Day's High
₹516.75Day's Low
₹514.7552 Week's High
₹052 Week's Low
₹0Book Value
₹-203.57Face Value
₹10Mkt Cap (₹ Cr.)
370.8P/E
0EPS
0Divi. Yield
0No Record Found
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 6.92 | 7.2 | 7.2 | 7.2 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -153.78 | -131.12 | -123.13 | -103.34 |
Net Worth | -146.86 | -123.92 | -115.93 | -96.14 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2017 | Mar-2016 | Mar-2015 | Mar-2014 |
---|---|---|---|---|
Revenue | 135.38 | 118.99 | 115.98 | 119.96 |
yoy growth (%) | 13.77 | 2.59 | -3.32 | 11.38 |
Raw materials | -46.44 | -40.62 | -41.17 | -41.5 |
As % of sales | 34.3 | 34.14 | 35.5 | 34.59 |
Employee costs | -24.56 | -22.44 | -17.67 | -15.88 |
Y/e 31 Mar( In .Cr) | Mar-2017 | Mar-2016 | Mar-2015 | Mar-2014 |
---|---|---|---|---|
Profit before tax | -13.82 | -23.77 | 20.88 | 30.06 |
Depreciation | -16.3 | -16.12 | -4.6 | -3.44 |
Tax paid | 0 | 5.23 | -3.87 | -10.55 |
Working capital | 6.71 | 0.76 | -24.6 | 19.6 |
Other operating items |
Y/e 31 Mar | Mar-2017 | Mar-2016 | Mar-2015 | Mar-2014 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 13.77 | 2.59 | -3.32 | 11.38 |
Op profit growth | 125.32 | -66.95 | -25.82 | 42.48 |
EBIT growth | -148.19 | -133.47 | -32 | 46.22 |
Net profit growth | -25.41 | -208.91 | -12.75 | 51.55 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,817.6 | 158.19 | 4,36,103.12 | 863.29 | 0.74 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,783.75 | 83.58 | 1,53,540.39 | 518 | 0.52 | 2,302 | 513.62 |
Mankind Pharma Ltd MANKIND | 2,910.4 | 59.91 | 1,20,073.47 | 634.43 | 0 | 2,529.74 | 334.18 |
Cipla Ltd CIPLA | 1,475.9 | 28.16 | 1,19,195.76 | 1,178.16 | 0.88 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,401.2 | 70.36 | 1,15,106.89 | 460 | 0.82 | 2,376 | 222.38 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director
SHIV CHARAN LAL GUPTA
Director
ARUN KUMAR GUPTA
Director
SUNINDER SINGH ARORA
Managing Director
INDRANIL MUKHERJEE
Director
ANDREAS WALDE
Additional Director
CHRISTOPH MUELLER
Company Secretary
RANJAN KUMAR SAHU
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ahlcon Parenterals India Ltd
Summary
Earlier known as Gujarat Inject, the company was incorporated on 20 Jan.92. It has been promoted by Ahluwalia Contracts and Bikramjit Ahluwalia.It manufactures and markets IV fluids. Intravenous fluid solutions are manufactured both by the organised and unorganised sector. The fluids are packed in aseptic plastic/glass bottles and in pouches manufactured by the unorganised sector. The product mix of various IV fluids manufactured by the company comprises injection dextrose 5%, dextrose saline / normal saline, dextrose 10%, lactate solution and multiple electrolyte solutions. IV fluids besides being injected into patients for post- and pre-operative care, are also used in cases of de-hydration, weakness, etc.IV fluids are generally sold through dealers. The company has tied-up for technical know-how from Gujarat Inject. It came out with a public issue in Jan.94 to part-finance an IV fluid project with an installed capacity of 14 mln bottles pa. Ahlcon, initially set up with an installed capacity of 14 mln bottles pa, was planned further to increase the capacity of 21 mln bottles p.a. The company diversified into opthalmic/ear care products by creating additional capacities of 200 lacs bottles in small volume parentals. It has also carried on a 2nd phase of expansion in both LVP and SVP with a additional capacity of 180 lacs bottles and 480 lacs bottles respectively. The commercial production has already been started.
Read More
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice